- Fresenius Medical Care AG & Co (NYSE:FMS) has agreed to merge its U.S. unit Fresenius Health Partners with medical services groups InterWell Health and Cricket Health to expand in the care of earlier stages of kidney disease.
- The new company, which will be fully consolidated by Fresenius Medical Care as the majority owner and operate under the InterWell Health brand, is valued at $2.4 billion.
- The merger brings together Fresenius Health Partners, InterWell Health's clinical care models, a strong network of 1,600 nephrologists, and Cricket Health's tech-enabled care model that utilizes the StageSmart platform.
- Related: Fresenius's Q4 Operating Income Hit By COVID-19 Related Headwinds, Targets Earnings Growth In FY22.
- The three-way merger would increase Fresenius Medical Care's total addressable market in the U.S. from around $50 billion to around $170 billion, the statement said.
- Financial terms were not disclosed. FMS expects the transaction could close in the second half of this year.
- Rice Powell, CEO of Fresenius Medical Care, said: "This effort is an important next step in executing Fresenius Medical Care's growth strategy 2025 to further expand along the renal care continuum."
- Price Action: FMS shares are down 2.36% at $32.72 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Fresenius Medical Care's US Unit Announces $2.4B Three-Way Merger Agreement
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks